# Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

> **NCT04548791** · PHASE1,PHASE2 · TERMINATED · sponsor: **Catalyst Biosciences** · enrollment: 19 (actual)

## Conditions studied

- Factor VII Deficiency
- Glanzmann Thrombasthenia
- Hemophilia A With Inhibitor

## Interventions

- **BIOLOGICAL:** Coagulation Factor VIIa variant

## Key facts

- **NCT ID:** NCT04548791
- **Lead sponsor:** Catalyst Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-17
- **Primary completion:** 2021-11-15
- **Final completion:** 2021-12-03
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Company decision (not a safety issue)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04548791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04548791, "Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04548791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*